First human test of Pfizer's new cancer drug begins

NCT ID NCT06799533

Summary

This early-stage study tested the safety and determined the right dosage of a new drug called PF-08046031 for adults with advanced melanoma and other solid tumors that have spread and have no other approved treatment options. The main goal was to identify side effects and see how the body processes the drug. The study was terminated early and did not progress to later phases to fully test how well the drug works against cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Gustave Roussy

    Villejuif, Val-de-marne, 94800, France

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona [barcelona], 08035, Spain

  • Karolinska Universitetssjukhuset Solna

    Solna, Stockholms LÄN [se-01], 171 64, Sweden

  • Presbyterian/ St. Lukes Medical Center

    Denver, Colorado, 80218, United States

  • Sarah Cannon Research Institute at HealthONE - SCRI - PPDS

    Denver, Colorado, 80218, United States

  • The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate

    Los Angeles, California, 90025, United States

  • The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate

    Los Angeles, California, 90025, United States

  • The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate (Emergency Back-up only)

    Santa Monica, California, 90404, United States

  • The Royal Marsden NHS Foundation Trust

    Sutton, SM2 5PT, United Kingdom

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California, 94143, United States

  • UCSF Medical Center, Investigational Pharmacy

    San Francisco, California, 94158, United States

Conditions

Explore the condition pages connected to this study.